Literature DB >> 15649892

Peroxisome proliferator-activated receptor gamma-independent activation of p38 MAPK by thiazolidinediones involves calcium/calmodulin-dependent protein kinase II and protein kinase R: correlation with endoplasmic reticulum stress.

Olivia S Gardner1, Chung-Wai Shiau, Ching-Shih Chen, Lee M Graves.   

Abstract

The thiazolidinediones (TZDs) are synthetic peroxisome proliferator-activated receptor gamma (PPARgamma) ligands that promote increased insulin sensitivity in type II diabetic patients. In addition to their ability to improve glucose homeostasis, TZDs also exert anti-proliferative effects by a mechanism that is unclear. Our laboratory has shown that two TZDs, ciglitazone and troglitazone, rapidly induce calcium-dependent p38 mitogen-activated protein kinase (MAPK) phosphorylation in liver epithelial cells. Here, we further characterize the mechanism responsible for p38 MAPK activation by PPARgamma ligands and correlate this with the induction of endoplasmic reticulum (ER) stress. Specifically, we show that TZDs rapidly activate the ER stress-responsive pancreatic eukaryotic initiation factor 2alpha (eIF2alpha) kinase or PKR (double-stranded RNA-activated protein kinase)-like endoplasmic reticulum kinase/pancreatic eIF2alpha kinase, and that activation of these kinases is correlated with subsequent eIF2alpha phosphorylation. Interestingly, PPARgamma ligands not only activated calcium/calmodulin-dependent kinase II (CaMKII) 2-fold over control, but the selective CaMKII inhibitor, KN-93, attenuated MKK3/6 and p38 as well as PKR and eIF2alpha phosphorylation. Although CaMKII was not affected by inhibition of PKR with 2-aminopurine, phosphorylation of MKK3/6 and p38 as well as eIF2alpha were significantly reduced. Collectively, these data provide evidence that CaMKII is a regulator of PKR-dependent p38 and eIF2alpha phosphorylation in response to ER calcium depletion by TZDs. Furthermore, using structural derivatives of TZDs that lack PPARgamma ligand-binding activity as well as a PPARgamma antagonist, we show that activation of these kinase signaling pathways is PPARgamma-independent.

Entities:  

Keywords:  Non-programmatic

Mesh:

Substances:

Year:  2005        PMID: 15649892     DOI: 10.1074/jbc.M410445200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  25 in total

1.  Rosiglitazone inhibits acyl-CoA synthetase activity and fatty acid partitioning to diacylglycerol and triacylglycerol via a peroxisome proliferator-activated receptor-gamma-independent mechanism in human arterial smooth muscle cells and macrophages.

Authors:  Bardia Askari; Jenny E Kanter; Ashley M Sherrid; Deidre L Golej; Andrew T Bender; Joey Liu; Willa A Hsueh; Joseph A Beavo; Rosalind A Coleman; Karin E Bornfeldt
Journal:  Diabetes       Date:  2007-01-26       Impact factor: 9.461

2.  Rosiglitazone causes cardiotoxicity via peroxisome proliferator-activated receptor γ-independent mitochondrial oxidative stress in mouse hearts.

Authors:  Huamei He; Hai Tao; Hui Xiong; Sheng Zhong Duan; Francis X McGowan; Richard M Mortensen; James A Balschi
Journal:  Toxicol Sci       Date:  2014-01-21       Impact factor: 4.849

3.  The role of CaMKII in calcium-activated death pathways in bone marrow B cells.

Authors:  Stephanie L Bissonnette; Amelia Haas; Koren K Mann; Jennifer J Schlezinger
Journal:  Toxicol Sci       Date:  2010-09-01       Impact factor: 4.849

4.  Toxicant-mediated redox control of proteostasis in neurodegeneration.

Authors:  Stefanos Aivazidis; Colin C Anderson; James R Roede
Journal:  Curr Opin Toxicol       Date:  2018-12-28

5.  G Protein-coupled Receptor 40 (GPR40) and Peroxisome Proliferator-activated Receptor γ (PPARγ): AN INTEGRATED TWO-RECEPTOR SIGNALING PATHWAY.

Authors:  Shuibang Wang; Keytam S Awad; Jason M Elinoff; Edward J Dougherty; Gabriela A Ferreyra; Jennifer Y Wang; Rongman Cai; Junfeng Sun; Anetta Ptasinska; Robert L Danner
Journal:  J Biol Chem       Date:  2015-06-23       Impact factor: 5.157

Review 6.  Roles of zinc and metallothionein-3 in oxidative stress-induced lysosomal dysfunction, cell death, and autophagy in neurons and astrocytes.

Authors:  Sook-Jeong Lee; Jae-Young Koh
Journal:  Mol Brain       Date:  2010-10-26       Impact factor: 4.041

7.  The activity of atorvastatin and rosiglitazone on CD38, ZAP70 and apoptosis in lymphocytes of B-cell chronic lymphocytic leukemia in vitro.

Authors:  Irfan Yavasoglu; Gokhan Sargin; Gurhan Kadikoylu; Aslihan Karul; Zahit Bolaman
Journal:  Med Oncol       Date:  2013-05-19       Impact factor: 3.064

8.  Effect of pioglitazone treatment on endoplasmic reticulum stress response in human adipose and in palmitate-induced stress in human liver and adipose cell lines.

Authors:  Swapan K Das; Winston S Chu; Ashis K Mondal; Neeraj K Sharma; Philip A Kern; Neda Rasouli; Steven C Elbein
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-06-10       Impact factor: 4.310

9.  Rat Urinary Bladder Carcinogenesis by Dual-Acting PPARalpha + gamma Agonists.

Authors:  Martin B Oleksiewicz; Jennifer Southgate; Lars Iversen; Frederikke L Egerod
Journal:  PPAR Res       Date:  2009-01-28       Impact factor: 4.964

10.  Pioglitazone enhances collateral blood flow in ischemic hindlimb of diabetic mice through an Akt-dependent VEGF-mediated mechanism, regardless of PPARgamma stimulation.

Authors:  Federico Biscetti; Giuseppe Straface; Vincenzo Arena; Egidio Stigliano; Giovanni Pecorini; Paola Rizzo; Giulia De Angelis; Luigi Iuliano; Giovanni Ghirlanda; Andrea Flex
Journal:  Cardiovasc Diabetol       Date:  2009-09-08       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.